The popularity of our top 10 blog posts is a testament to the promising advances Parkinson's research made this year. Scientists are developing and testing new ways to stop disease progression and to treat the symptoms people live with today. We love that among the research news our users responded to a post on positivity, too.†
Our top blog post of the year announced that the first Parkinsonís vaccine in clinical trials ó a treatment that could slow or stop the disease process
ó was found safe and tolerable.
A new partnership between the Foundation and Intel aims to collect
Parkinsonís disease data through wearable devices like smart watches and
A clinical trial of isradipine ó an available hypertension drug ó is testing its
ability to slow Parkinsonís progression and began recruiting volunteers in October.
More than 250 scientists working on Parkinsonís disease discussed the most promising research developments at the MJFF annual conference in October.
Podcast guests share more about the hypertension drug isradipine, now in
Phase III testing for impact on Parkinsonís disease.
This blog post describes approaches to stop Parkinsonís progression by targeting alpha-synuclein, the sticky protein that clumps in the brain cells of people with PD.
Researchers are working on a less-invasive alternative to deep brain stimulation that may offer the same relief of motor symptoms.
Like many people with Parkinsonís, guest blogger Bryan Roberts is inspired by Michael J. Foxís optimism. He shares his experience of coming to terms with his PD and choosing his outlook.
In July, scientists reported that theyíd identified 28 genetic risk factors for Parkinsonís disease, including six that had not been named before.
A third blog post on isradipine made it into our top 10 list, after the drug was highlighted on a CBS News New York special on Parkinsonís research.†